Date: 19 May 2026 | Category: News
Vapourtec has installed a Peptide-Builder™ system in Professor Peter ’t Hart’s research group at the University of Münster, Germany. The system is now fully operational and supporting advanced research into targeting protein–RNA interactions (RPIs) for therapeutic applications.
Dr. ’t Hart’s group focuses on developing innovative peptide-based tools and therapeutics to address challenging protein–RNA interactions implicated in diseases such as cancer and neurodegeneration. Their research integrates molecular biochemistry, chemical biology, and advanced peptide design to create macrocyclic and stapled peptides with enhanced stability and cellular activity. Peptide synthesis underpins this work, enabling the rapid development and evaluation of novel bioactive peptides for RNA biology and therapeutic discovery.
Using the Peptide-Builder™, the group is synthesising peptides in the 10–40 amino acid range sequences that are often prone to aggregation and reduced coupling efficiency when produced using conventional batch methods. Fast-flow solid-phase peptide synthesis (SPPS) offers enhanced control over reaction conditions, resulting in higher crude purity and improved access to complex and demanding sequences.
The system’s in-line UV/Vis monitoring, peptide volume data, and comprehensive data capture provide real-time insight into deprotection efficiency and aggregation behaviour, enabling data-driven optimisation and increasing confidence in synthesis outcomes. Combined with an intuitive graphical interface, researchers gain enhanced visibility into synthesis performance and process consistency throughout the run, providing clear feedback to support optimisation strategies and process development.
In a multi-user research environment, the open-access capability is particularly valuable, allowing peptides to be queued throughout the day and over weekends. This flexibility helps streamline workflows and maximise productivity across the group.
Vapourtec looks forward to continuing its collaboration with Professor ’t Hart’s team as they advance research into protein–RNA interactions and the development of next-generation peptide therapeutics.
Request a demo for the Peptide-Builder